Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction

Area of Science:

• Cardiovascular Pharmacology
• Clinical Trial Analysis
• Drug Safety and Efficacy

Background:

• Long-term treatment with ticagrelor is used in patients with prior myocardial infarction (MI).
• Understanding drug exposure-response relationships is crucial for optimizing treatment and minimizing risks.

Purpose of the Study:

• To estimate the relationships between ticagrelor exposure and the composite risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke.
• To assess the risk of TIMI major bleeding in relation to ticagrelor exposure.
• To support primary efficacy and safety evaluations and inform optimal dosing strategies.

Main Methods:

• Analysis of data from 20,942 patients with prior MI treated with ticagrelor 60 mg or 90 mg twice daily.
• Exposure-response modeling to evaluate the impact of individual drug exposure levels on clinical outcomes.
• Comparison of predicted risks of CV death/MI/stroke and TIMI major bleeding across different ticagrelor exposure levels and doses versus placebo.

Main Results:

• Clear separation from placebo for both cardiovascular events and bleeding risk was observed early in treatment with both ticagrelor doses.
• Predicted risks for CV death/MI/stroke were similar between ticagrelor 60 mg and 90 mg despite differences in median exposure.
• Predicted risk of TIMI major bleeding slightly increased with higher ticagrelor exposure.
• Ticagrelor's response was consistent across most patient subgroups, with Japanese patients showing a lower risk of CV events.

Conclusions:

• Exposure-response analyses confirm early efficacy and safety findings for ticagrelor.
• Individual drug exposure, rather than just dose, is a key predictor of clinical events.
• The 60-mg dose of ticagrelor is supported for all studied demographic subgroups due to its favorable risk-benefit profile and consistent efficacy across exposure levels.